| Russell S Kelly, MD | |
|
91-2139 Fort Weaver Rd, Suite 300, Ewa Beach, HI 96706-3607 | |
| (808) 678-0700 | |
| (808) 678-0776 |
| Full Name | Russell S Kelly |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 44 Years |
| Location | 91-2139 Fort Weaver Rd, Ewa Beach, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790787729 | NPI | - | NPPES |
| 0000241885 | Medicaid | HI | |
| 539207 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 11807 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Queens Medical Center | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Russell S Kelly Md Llc | 2365548781 | 2 |
| Medical Office Force | 9335481951 | 41 |
News Archive
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
› Verified 3 days ago
| Entity Name | Russell S Kelly Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598810814 PECOS PAC ID: 2365548781 Enrollment ID: O20070502000010 |
News Archive
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
› Verified 3 days ago
| Entity Name | Medical Office Force |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508378613 PECOS PAC ID: 9335481951 Enrollment ID: O20211012003040 |
News Archive
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Russell S Kelly, MD 91-2139 Fort Weaver Rd, Suite 300, Ewa Beach, HI 96706-3607 Ph: (808) 678-0700 | Russell S Kelly, MD 91-2139 Fort Weaver Rd, Suite 300, Ewa Beach, HI 96706-3607 Ph: (808) 678-0700 |
News Archive
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
› Verified 3 days ago
Mr. Kevin Marc Salire, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706 Phone: 808-691-3340 Fax: 808-691-3345 | |
Dr. Brian Hunter Levins Jr., M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 91-2301 Old Ft Weaver Rd, Ewa Beach, HI 96706 Phone: 808-677-2587 | |
Mrs. Aurora C Mariani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 91-2139 Fort Weaver Rd. #307, Ewa Beach, HI 96706 Phone: 808-680-0008 Fax: 808-680-0049 | |
Laverne Arabella Kia, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 912139 Fort Weaver Road, Suite 209, Ewa Beach, HI 96706 Phone: 808-671-4530 Fax: 808-676-1066 | |
Dr. Kimberly Kyle, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-691-3000 | |
Albert Lin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-678-7000 | |
Daniel K Chan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706 Phone: 808-691-3150 Fax: 808-691-3153 |